Exploring Immunotherapy Strategies in SCAC and MCC

Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.

Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.

Marwan G. Fakih, MD, discusses the shift in SCAC management after the approval of retifanlimab and the resulting need for better second-line strategies.

Marwan G. Fakih, MD, discusses the implications of the FDA approval of retifanlimab plus chemotherapy for the evolving role of immunotherapy in SCAC.

Richard Kim, MD, discusses how data from the phase 3 POD1UM-303 trial inform the use of retifanlimab plus chemotherapy in frontline metastatic SCAC.

Richard D. Kim, MD, discusses how positive results from PODIUM-303 exemplify and support the shift towards chemoimmunotherapy regimens in frontline SCAC.